Related Experiment Video
Updated: Mar 17, 2026

12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
6.9K
Recurrent retroperitoneal inflammatory myofibroblastic tumor: A case report
Xinjun Wang1, Xiaokun Zhao2, Joseph Chin3
1Department of Urology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, P.R. China.
Oncology Letters
|July 23, 2016
Summary
Recurrent inflammatory myofibroblastic tumor (IMT) in a 74-year-old female was successfully re-resected. Complete surgical removal is recommended for primary and recurrent IMT.
Area of Science:
- Oncology
- Pathology
Background:
- Inflammatory myofibroblastic tumor (IMT), previously known as inflammatory pseudotumor, is a rare neoplasm.
- IMT is characterized by myofibroblastic spindle cells and inflammatory infiltrates, with an unclear etiology.
- Clinical presentation of IMT is often non-specific.
Purpose of the Study:
- To report a case of recurrent inflammatory myofibroblastic tumor.
- To highlight the successful management of a complex IMT case.
- To emphasize the importance of complete surgical resection for IMT.
Main Methods:
- Case report of a 74-year-old female patient with recurrent IMT.
- Description of clinical presentation including left hydroureteronephrosis and a large paravertebral mass involving the descending colon.
- Surgical intervention involving complete en bloc re-resection of the tumor.
Main Results:
- The patient underwent successful re-resection of a recurrent IMT 30 months after initial surgery.
- The tumor involved the descending colon and caused left hydroureteronephrosis.
- At 24 months post-surgery, the patient remained disease-free.
Conclusions:
- Complete surgical extirpation is the recommended treatment for both primary and recurrent inflammatory myofibroblastic tumors.
- Early and complete surgical removal can lead to favorable outcomes in IMT management.
- This case underscores the efficacy of surgical intervention in managing recurrent IMT.